What changed: Head and neck squamous cell carcinoma
Every dated change on the records linked to Head and neck squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 1
2025 · 4
- 2025Trial resultKEYNOTE-689KEYNOTE-689 reported
Median EFS 59.
- 2025Trial resultNRG-HN002 & NRG-HN005 (HPV+ de-escalation)NRG-HN002 & NRG-HN005 (HPV+ de-escalation) reported
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
- 2025MilestoneKEYNOTE-689KEYNOTE-689 perioperative pembrolizumab approved; NRG-HN005 de-escalation fails; petosemtamab and ficerafusp alfa phase 3 trials
A milestone in how this cancer is treated.
- 2025MilestoneHead and neck squamous cell carcinomaKEYNOTE-689: neoadjuvant IO
A milestone in how this cancer is treated.
2024 · 2
2023 · 2
2022 · 1
2021 · 2
September 2020 · 1
2020 · 4
- 2020ApprovalCetuximab sarotalocanCetuximab sarotalocan approved in Japan
Unresectable locally advanced or recurrent head and neck cancer (conditional)
- 2020Trial resultJAVELIN Head and Neck 100JAVELIN Head and Neck 100 reported
PFS HR 1.
- 2020Trial resultOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) reported
Median OS 7.
- 2020MilestoneCetuximab sarotalocanCetuximab sarotalocan photoimmunotherapy approved in Japan; JAVELIN H&N 100 negative
A milestone in how this cancer is treated.
2019 · 6
- 2019ApprovalPD-L1 IHC 22C3 pharmDxPD-L1 IHC 22C3 pharmDx approved in US
Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)
- 2019Trial resultDe-ESCALaTE HPVDe-ESCALaTE HPV reported
Severe toxicity similar; 2-year overall survival 97.
- 2019Trial resultKEYNOTE-048KEYNOTE-048 reported
OS 14.
- 2019Trial resultRTOG 1016RTOG 1016 reported
5-year overall survival 84.
- 2019MilestoneHead and neck squamous cell carcinomaKEYNOTE-048: IO first line
A milestone in how this cancer is treated.
- 2019MilestoneKEYNOTE-048KEYNOTE-048: pembrolizumab first line; RTOG 1016 and De-ESCALaTE show cetuximab cannot replace cisplatin
A milestone in how this cancer is treated.
2018 · 1
2016 · 3
- 2016Trial resultCheckMate 141CheckMate 141 reported
OS 7.
- 2016MilestoneCheckMate 141Nivolumab (CheckMate 141) and pembrolizumab approved after platinum
A milestone in how this cancer is treated.
- 2016MilestoneHead and neck squamous cell carcinomaPD-1 approved second line
A milestone in how this cancer is treated.
2015 · 1
2010 · 2
2009 · 1
2008 · 2
2006 · 4
- 2006ApprovalCetuximabCetuximab approved in US
Head and neck squamous cell carcinoma with radiation
- 2006Trial resultBonner trial (cetuximab plus radiotherapy)Bonner trial (cetuximab plus radiotherapy) reported
Median overall survival 49.
- 2006MilestoneEGFRCetuximab + radiation improves survival (Bonner)
First targeted agent in HNSCC.
- 2006MilestoneHead and neck squamous cell carcinomaCetuximab + RT
A milestone in how this cancer is treated.